EVLO Evelo Biosciences Inc

Evelo Biosciences Inc operates as a bio-technology company. The firm develops therapies for the treatment of the gut-body network. Evelo Biosciences also offers treatment for cancer and inflammatory diseases.

$9.55  +0.12 (1.27%)
As of 05/07/2021 15:58:56 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/09/2018
Outstanding shares:  53,373,882
Average volume:  291,137
Market cap:   $503,315,707
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    299734103
ISIN:        US2997341035
Sedol:      BFMFL82
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   5.80
PS ratio:   0.00
Return on equity:   -80.43%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy